These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 32376656)

  • 41. Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma.
    Ramzy GM; Norkin M; Koessler T; Voirol L; Tihy M; Hany D; McKee T; Ris F; Buchs N; Docquier M; Toso C; Rubbia-Brandt L; Bakalli G; Guerrier S; Huelsken J; Nowak-Sliwinska P
    J Exp Clin Cancer Res; 2023 Apr; 42(1):79. PubMed ID: 37013646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
    Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids.
    Schuster B; Junkin M; Kashaf SS; Romero-Calvo I; Kirby K; Matthews J; Weber CR; Rzhetsky A; White KP; Tay S
    Nat Commun; 2020 Oct; 11(1):5271. PubMed ID: 33077832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids.
    Phan N; Hong JJ; Tofig B; Mapua M; Elashoff D; Moatamed NA; Huang J; Memarzadeh S; Damoiseaux R; Soragni A
    Commun Biol; 2019; 2():78. PubMed ID: 30820473
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
    Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decellularized extracellular matrix as scaffold for cancer organoid cultures of colorectal peritoneal metastases.
    Varinelli L; Guaglio M; Brich S; Zanutto S; Belfiore A; Zanardi F; Iannelli F; Oldani A; Costa E; Chighizola M; Lorenc E; Minardi SP; Fortuzzi S; Filugelli M; Garzone G; Pisati F; Vecchi M; Pruneri G; Kusamura S; Baratti D; Cattaneo L; Parazzoli D; Podestà A; Milione M; Deraco M; Pierotti MA; Gariboldi M
    J Mol Cell Biol; 2023 Apr; 14(11):. PubMed ID: 36460033
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer.
    Norkin M; Ordóñez-Morán P; Huelsken J
    Cell Rep; 2021 Apr; 35(3):109026. PubMed ID: 33882314
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived Organoids.
    Putker M; Millen R; Overmeer R; Driehuis E; Zandvliet MMJM; Clevers H; Boj SF; Li QX
    J Vis Exp; 2021 Apr; (170):. PubMed ID: 33999032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Application of Cancer Organoid Model for Drug Screening and Personalized Therapy.
    Kondo J; Inoue M
    Cells; 2019 May; 8(5):. PubMed ID: 31108870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer.
    Toshimitsu K; Takano A; Fujii M; Togasaki K; Matano M; Takahashi S; Kanai T; Sato T
    Nat Chem Biol; 2022 Jun; 18(6):605-614. PubMed ID: 35273398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
    Votanopoulos KI; Forsythe S; Sivakumar H; Mazzocchi A; Aleman J; Miller L; Levine E; Triozzi P; Skardal A
    Ann Surg Oncol; 2020 Jun; 27(6):1956-1967. PubMed ID: 31858299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
    Vlachogiannis G; Hedayat S; Vatsiou A; Jamin Y; Fernández-Mateos J; Khan K; Lampis A; Eason K; Huntingford I; Burke R; Rata M; Koh DM; Tunariu N; Collins D; Hulkki-Wilson S; Ragulan C; Spiteri I; Moorcraft SY; Chau I; Rao S; Watkins D; Fotiadis N; Bali M; Darvish-Damavandi M; Lote H; Eltahir Z; Smyth EC; Begum R; Clarke PA; Hahne JC; Dowsett M; de Bono J; Workman P; Sadanandam A; Fassan M; Sansom OJ; Eccles S; Starling N; Braconi C; Sottoriva A; Robinson SP; Cunningham D; Valeri N
    Science; 2018 Feb; 359(6378):920-926. PubMed ID: 29472484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform.
    Xing F; Liu YC; Huang S; Lyu X; Su SM; Chan UI; Wu PC; Yan Y; Ai N; Li J; Zhao M; Rajendran BK; Liu J; Shao F; Sun H; Choi TK; Zhu W; Luo G; Liu S; Xu L; Chan KL; Zhao Q; Miao K; Luo KQ; Ge W; Xu X; Wang G; Liu TM; Deng CX
    Theranostics; 2021; 11(19):9415-9430. PubMed ID: 34646378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.
    Burkhart RA; Baker LA; Tiriac H
    Methods Mol Biol; 2018; 1787():253-261. PubMed ID: 29736724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Personalizing pancreatic cancer organoids with hPSCs.
    Zhang HC; Kuo CJ
    Nat Med; 2015 Nov; 21(11):1249-51. PubMed ID: 26540385
    [No Abstract]   [Full Text] [Related]  

  • 56. Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine.
    Taverna JA; Hung CN; Williams M; Williams R; Chen M; Kamali S; Sambandam V; Hsiang-Ling Chiu C; Osmulski PA; Gaczynska ME; DeArmond DT; Gaspard C; Mancini M; Kusi M; Pandya AN; Song L; Jin L; Schiavini P; Chen CL
    Lung Cancer; 2024 Apr; 190():107533. PubMed ID: 38520909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patient-Derived Organoids for Precision Cancer Immunotherapy.
    Grönholm M; Feodoroff M; Antignani G; Martins B; Hamdan F; Cerullo V
    Cancer Res; 2021 Jun; 81(12):3149-3155. PubMed ID: 33687948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a Colorectal Cancer 3D Micro-tumor Construct Platform From Cell Lines and Patient Tumor Biospecimens for Standard-of-Care and Experimental Drug Screening.
    Forsythe S; Mehta N; Devarasetty M; Sivakumar H; Gmeiner W; Soker S; Votanopoulos K; Skardal A
    Ann Biomed Eng; 2020 Mar; 48(3):940-952. PubMed ID: 31020445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.
    Vela CM; Knepper TC; Gillis NK; Walko CM; McLeod HL; Hicks JK
    Pharmacotherapy; 2017 Sep; 37(9):1043-1051. PubMed ID: 28235141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.
    Collignon A; Hospital MA; Montersino C; Courtier F; Charbonnier A; Saillard C; D'Incan E; Mohty B; Guille A; Adelaïde J; Carbuccia N; Garnier S; Mozziconacci MJ; Zemmour C; Pakradouni J; Restouin A; Castellano R; Chaffanet M; Birnbaum D; Collette Y; Vey N
    Blood Cancer J; 2020 Jun; 10(6):64. PubMed ID: 32488055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.